| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 03/07/2002 | WO2002018583A2 Modified polypeptides stabilized in a desired conformation and methods for producing same |
| 03/07/2002 | WO2002018581A2 G-protein coupled receptors |
| 03/07/2002 | WO2002018575A2 Genes expressed in the cell cycle |
| 03/07/2002 | WO2002018554A2 Isolated human drug-metabolizing proteins, nucleic acid moleculesand uses thereof |
| 03/07/2002 | WO2002018553A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 03/07/2002 | WO2002018540A2 Pyridine derivatives useful as cd40:cd154 binding interruptor compounds and use thereof to treat immunological complications |
| 03/07/2002 | WO2002018449A1 Nitroderivatives of polysaccharides |
| 03/07/2002 | WO2002018445A2 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| 03/07/2002 | WO2002018444A2 Erbb4 antagonists |
| 03/07/2002 | WO2002018440A1 Anti-angiogenic peptides |
| 03/07/2002 | WO2002018432A2 Protein extracted from the intestines of vertebrates, which absorbs cholesterol, and the use of this protein for identifying inhibitors of intestinal cholesterol transport |
| 03/07/2002 | WO2002018404A2 Nucleoside derivatives for the treatment of hepatitis c |
| 03/07/2002 | WO2002018395A1 Phosphate derivatives as immunoregulatory agents |
| 03/07/2002 | WO2002018389A2 Thienopyrimidine |
| 03/07/2002 | WO2002018386A1 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a]PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a]PYRIMIDIN-5(1H)ONE DERIVATI VES |
| 03/07/2002 | WO2002018383A2 Aza heterocyclic derivatives and their therapeutic use |
| 03/07/2002 | WO2002018382A1 Pyrazolopyridine compound and pharmaceutical use thereof |
| 03/07/2002 | WO2002018379A2 7-oxo pyridopyrimidines |
| 03/07/2002 | WO2002018378A1 Pyrrolidine derivatives and their use as chymase inhibitor |
| 03/07/2002 | WO2002018377A1 Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists |
| 03/07/2002 | WO2002018361A2 Compounds having activity as inhibitors of cytochrome p450rai |
| 03/07/2002 | WO2002018355A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists |
| 03/07/2002 | WO2002018350A1 Grk inhibitor |
| 03/07/2002 | WO2002018343A1 Method for synthesizing flosequinan from 4-fluoroanthranilic acid |
| 03/07/2002 | WO2002018341A2 Quinoline- (c=o) - (di-, tri- and tetrapeptide) derivatives as caspase inhibitors |
| 03/07/2002 | WO2002018340A1 GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS |
| 03/07/2002 | WO2002017967A1 Method of increasing testosterone and related steroid concentrations in women |
| 03/07/2002 | WO2002017951A1 Method for treating the central nervous system by administration of igf structural analogs |
| 03/07/2002 | WO2002017945A1 Efficient method for producing compositions enriched in anthocyanins |
| 03/07/2002 | WO2002017927A1 Method for treating erectile dysfunction and increasing libido in men |
| 03/07/2002 | WO2002017914A2 Fused pyrrolocarbazoles against inflammation |
| 03/07/2002 | WO2002017912A1 Endothelin antagonists |
| 03/07/2002 | WO2002017899A2 Regulation of angiogenesis via modulation of edg receptor mediated signal transduction comprising sphingosine-1-phosphate administration |
| 03/07/2002 | WO2002017898A2 Compositions and methods for inducing vasorelaxation |
| 03/07/2002 | WO2002017893A2 Sgk2 and sgk3 used as diagnostic and therapeutic targets |
| 03/07/2002 | WO2002017892A2 Water-dispersible encapsulated sterols |
| 03/07/2002 | WO2002017891A2 Method for diagnosing neuronal diseases and for treating primary hemostasis deficiency |
| 03/07/2002 | WO2002017880A2 Nitric oxide-producing hydrogel materials |
| 03/07/2002 | WO2002017878A1 Lung surfactant compositions with dynamic swelling behaviour |
| 03/07/2002 | WO2002017857A2 Methods and compositions for inhibiting angiogenesis |
| 03/07/2002 | WO2002017732A2 Efficient method for producing compositions enriched in anthocyanins |
| 03/07/2002 | WO2001094420B1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 03/07/2002 | WO2001093911A3 Macromolecular drug complexes and compositions containing the same |
| 03/07/2002 | WO2001090103A9 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as protein kinase modulators |
| 03/07/2002 | WO2001079269A3 Lipid binding protein 4 |
| 03/07/2002 | WO2001078757A3 Reversible immortalization |
| 03/07/2002 | WO2001078649A3 Pharmaceutical curative compound |
| 03/07/2002 | WO2001077100A3 Benzoamide piperidine compounds as substance p antagonists |
| 03/07/2002 | WO2001068033A3 Il-8 receptor antagonists |
| 03/07/2002 | WO2001062236A3 New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent |
| 03/07/2002 | WO2001060414A3 Genetic modification of the lung as a portal for gene delivery |
| 03/07/2002 | WO2001058956A3 Antibodies that bind human interleukin-18 and methods of making and using |
| 03/07/2002 | WO2001057022A3 Pyrazole compositions useful as inhibitors of erk |
| 03/07/2002 | WO2001055692A3 Neurosteroids as markers for alzheimer's disease |
| 03/07/2002 | WO2001051636A3 Secreted proteins |
| 03/07/2002 | WO2001046166A3 Partially saturated calcium channel blockers |
| 03/07/2002 | WO2001032888A3 Human transferase molecules |
| 03/07/2002 | WO2001031008A3 Human and rat fgf-20 genes and gene expression products |
| 03/07/2002 | WO2001023377A3 Polymorphic salt |
| 03/07/2002 | WO2001021163A3 Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents |
| 03/07/2002 | WO2001015673A3 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure |
| 03/07/2002 | WO2001011086A3 Methods of screening for angiogenesis modulators |
| 03/07/2002 | US20020028951 Process for preparing eprosartan |
| 03/07/2002 | US20020028940 Also benzimidazolyl and imidazo(4,5-b)pyridinyl-substituted; amides; antiatherosclerotic; reduces smooth muscle cell proliferation as well as reduction in lipoproteins, cholesterol and triglycerides |
| 03/07/2002 | US20020028851 Guanylhydrazones and their use to treat inflammatory conditions |
| 03/07/2002 | US20020028848 Administering orally 13-hydroxyoctadeca-9Z,11E-dienoic acid (13-HODE); anticoagulants; cardiovascular, respiratory, gastrointestinal, nervous and psyiatric disorders; autoimmune disease; antiinflammatory agents; bactericides; viricides |
| 03/07/2002 | US20020028846 Compositions and methods for amelioration of human female sexual dysfunction |
| 03/07/2002 | US20020028841 Thienopyrrolidinones |
| 03/07/2002 | US20020028836 Potassium channel openers |
| 03/07/2002 | US20020028835 Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| 03/07/2002 | US20020028828 (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors |
| 03/07/2002 | US20020028826 HMG-CoA reductase inhibitors and method |
| 03/07/2002 | US20020028821 Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-ht1a- and/or 5-ht1d receptors |
| 03/07/2002 | US20020028818 2-nitrostyryl-1-(naphthylmethyl)sulfone for example |
| 03/07/2002 | US20020028817 Platelet derived growth factors (PDGF); 1,2-dimethyl-6-(2-thiophene)imidazolo(5,4-g)quinoxaline preparations for example; use treating proliferative malignant and non-malignant diseases; stents |
| 03/07/2002 | US20020028815 Novel multicyclic compounds and the use thereof |
| 03/07/2002 | US20020028803 Controlling cell apoptosis |
| 03/07/2002 | US20020028793 Antilipemic agents, anticholesterol agents, anticoagulants |
| 03/07/2002 | US20020028790 Use of agonists or antagonists of P2 purinoceptors for the prevention glutamate-evoked cytotoxicity |
| 03/07/2002 | US20020028787 Nervous system disorders; administering exogenous uridine compound |
| 03/07/2002 | US20020028782 Cardiovascular disorders; nervous system disorders |
| 03/07/2002 | US20020028774 C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| 03/07/2002 | US20020028772 Modulation of metabolism |
| 03/07/2002 | US20020028760 Nervous system disorders; hypotensive agents; incontinence |
| 03/07/2002 | US20020028510 Cells for use in the treatment of nervous system disorders |
| 03/07/2002 | US20020028436 Suppression of leukocyte transferring in humans; administer immunoglobulins to humans, detect bound receptor, evaluate immune response |
| 03/07/2002 | US20020028212 Recombinant viruses coding for a glutamate decarboxylase (gad) activity |
| 03/07/2002 | US20020028199 Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein C (APC) |
| 03/07/2002 | US20020028190 Compositions of non-ionic block copolymers to treat autoimmune, proliferative, and inflammatory diseases and methods of use thereof |
| 03/07/2002 | DE10041574A1 Chromenonderivate Chromenonderivate |
| 03/07/2002 | DE10041428A1 Biphenylderivate Biphenyl |
| 03/07/2002 | DE10041423A1 Biphenylderivate Biphenyl |
| 03/07/2002 | DE10041238A1 Verfahren zur Identifizierung spezifisch spaltbarer peptide und Verwendung solcher Peptidsequenzen A method for identifying specific cleavable peptide and use of such peptide sequences |
| 03/07/2002 | DE10040783A1 AZA-Aminosäurederivate (Faktor X¶a¶-Inhibitoren 15) AZA-amino acid derivatives (factor inhibitors X¶a¶ 15) |
| 03/07/2002 | DE10038043A1 Phamakologisch wirksame Substanz zur Behandlung kardiovaskulärer Erkrankungen Of pharmacologically active substance for the treatment of cardiovascular diseases |
| 03/07/2002 | CA2746787A1 Method of increasing testosterone and related steroid concentrations in women |
| 03/07/2002 | CA2421893A1 Phosphate derivatives as immunoregulatory agents |
| 03/07/2002 | CA2421503A1 Methods and compositions for inhibiting angiogenesis |
| 03/07/2002 | CA2421055A1 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| 03/07/2002 | CA2420869A1 Compounds having activity as inhibitors of cytochrome p450rai |